161 related articles for article (PubMed ID: 23299761)
1. Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients.
Wooten JS; Nambi P; Gillard BK; Pownall HJ; Coraza I; Scott LW; Nambi V; Ballantyne CM; Balasubramanyam A
Med Sci Sports Exerc; 2013 Jun; 45(6):1043-50. PubMed ID: 23299761
[TBL] [Abstract][Full Text] [Related]
2. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial.
Balasubramanyam A; Coraza I; Smith EO; Scott LW; Patel P; Iyer D; Taylor AA; Giordano TP; Sekhar RV; Clark P; Cuevas-Sanchez E; Kamble S; Ballantyne CM; Pownall HJ
J Clin Endocrinol Metab; 2011 Jul; 96(7):2236-47. PubMed ID: 21565796
[TBL] [Abstract][Full Text] [Related]
3. Short-term fenofibrate treatment reduces elevated plasma Lp-PLA2 mass and sVCAM-1 levels in a subcohort of hypertriglyceridemic GOLDN participants.
Tsai AK; Steffen BT; Ordovas JM; Straka R; Zhou X; Hanson NQ; Arnett D; Tsai MY
Transl Res; 2011 Aug; 158(2):99-105. PubMed ID: 21757154
[TBL] [Abstract][Full Text] [Related]
4. Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome.
Rosenson RS
Am Heart J; 2008 Mar; 155(3):499.e9-16. PubMed ID: 18294485
[TBL] [Abstract][Full Text] [Related]
5. Effects of Extended-Release Niacin on Quartile Lp-PLA
Lyubarova R; Albers JJ; Marcovina SM; Yao Y; McBride R; Topliceanu A; Anderson T; Fleg JL; Desvigne-Nickens P; Kashyap ML; McGovern ME; Boden WE
J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):534-541. PubMed ID: 31131629
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein-associated phospholipase A2, a novel cardiovascular inflammatory marker, in HIV-infected patients.
Mangili A; Ahmad R; Wolfert RL; Kuvin J; Polak JF; Karas RH; Wanke CA
Clin Infect Dis; 2014 Mar; 58(6):893-900. PubMed ID: 24336757
[TBL] [Abstract][Full Text] [Related]
7. Heart positive: design of a randomized controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia.
Samson SL; Pownall HJ; Scott LW; Ballantyne CM; Smith EO; Sekhar RV; Balasubramanyam A
Contemp Clin Trials; 2006 Dec; 27(6):518-30. PubMed ID: 16914390
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein-associated phospholipase A2 and cardiovascular disease risk in HIV infection.
Ross Eckard A; Longenecker CT; Jiang Y; Debanne SM; Labbato D; Storer N; McComsey GA
HIV Med; 2014 Oct; 15(9):537-46. PubMed ID: 24650269
[TBL] [Abstract][Full Text] [Related]
9. The effect of a 12-week course of omega-3 polyunsaturated fatty acids on lipid parameters in hypertriglyceridemic adult HIV-infected patients undergoing HAART: a randomized, placebo-controlled pilot trial.
Peters BS; Wierzbicki AS; Moyle G; Nair D; Brockmeyer N
Clin Ther; 2012 Jan; 34(1):67-76. PubMed ID: 22212377
[TBL] [Abstract][Full Text] [Related]
10. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.
Saougos VG; Tambaki AP; Kalogirou M; Kostapanos M; Gazi IF; Wolfert RL; Elisaf M; Tselepis AD
Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2236-43. PubMed ID: 17656665
[TBL] [Abstract][Full Text] [Related]
11. Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial.
Kei A; Liberopoulos E; Tellis K; Rizzo M; Elisaf M; Tselepis A
Eur J Clin Invest; 2013 Jul; 43(7):698-707. PubMed ID: 23600368
[TBL] [Abstract][Full Text] [Related]
12. PPAR-α Agonist Fenofibrate Decreased RANTES Levels in Type 2 Diabetes Patients with Hypertriglyceridemia.
Feng X; Gao X; Jia Y; Zhang H; Xu Y; Wang G
Med Sci Monit; 2016 Mar; 22():743-51. PubMed ID: 26944934
[TBL] [Abstract][Full Text] [Related]
13. Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186.
Gerber JG; Kitch DW; Fichtenbaum CJ; Zackin RA; Charles S; Hogg E; Acosta EP; Connick E; Wohl D; Kojic EM; Benson CA; Aberg JA
J Acquir Immune Defic Syndr; 2008 Apr; 47(4):459-66. PubMed ID: 17971707
[TBL] [Abstract][Full Text] [Related]
14. [HIV-infection, HAART (highly-active antiretroviral therapy) and hyperlipidemia].
Hirsch HH; Battegay M
Dtsch Med Wochenschr; 2003 May; 128(19):1051-4. PubMed ID: 12736856
[TBL] [Abstract][Full Text] [Related]
15. Elevated circulating levels of lipoprotein-associated phospholipase A2 in obese children.
Sakka S; Siahanidou T; Voyatzis C; Pervanidou P; Kaminioti C; Lazopoulou N; Kanaka-Gantenbein C; Chrousos GP; Papassotiriou I
Clin Chem Lab Med; 2015 Jun; 53(7):1119-25. PubMed ID: 25581763
[TBL] [Abstract][Full Text] [Related]
16. Differential Reduction in Monocyte Activation and Vascular Inflammation With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among HIV-Infected Individuals.
Hileman CO; Kinley B; Scharen-Guivel V; Melbourne K; Szwarcberg J; Robinson J; Lederman MM; Mccomsey GA
J Infect Dis; 2015 Aug; 212(3):345-54. PubMed ID: 25583168
[TBL] [Abstract][Full Text] [Related]
17. Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mg.
Wi J; Kim JY; Park S; Kang SM; Jang Y; Chung N; Shim WH; Cho SY; Lee SH
Atherosclerosis; 2010 Nov; 213(1):235-40. PubMed ID: 20855072
[TBL] [Abstract][Full Text] [Related]
18. Lipoprotein-associated phospholipase A2 mass is significantly reduced in dyslipidemic patients treated with lifestyle modification and combination lipid-modifying drug therapy.
Reddy KJ; Singh M; Batsell RR; Bangit JR; Miraskar RA; Zaheer MS
Prev Cardiol; 2010; 13(3):130-4. PubMed ID: 20626668
[TBL] [Abstract][Full Text] [Related]
19. The relation between Lp-PLA2 levels with periodic limb movements.
Bekci TT; Kayrak M; Kiyici A; Ari H; Teke T; Maden E; Akilli H
Sleep Breath; 2012 Mar; 16(1):117-22. PubMed ID: 21221825
[TBL] [Abstract][Full Text] [Related]
20. Lp-PLA2: inflammatory biomarker of vascular risk in multiple sclerosis.
Sternberg Z; Drake A; Sternberg DS; Benedict RH; Li F; Hojnacki D; Weinstock-Guttmann B; Munschauer FE
J Clin Immunol; 2012 Jun; 32(3):497-504. PubMed ID: 22246459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
